BACKGROUND: Heart failure remains a significant problem. Tissue-engineered cardiac patches offer potential to treat severe heart failure. We studied an extracellular matrix scaffold for repairing the infarcted left ventricle. METHODS AND RESULTS: Pigs (n=42) underwent left ventricular (LV) infarction. At 6 to 8 weeks, either 4-layer multilaminate urinary bladder-derived extracellular matrix or expanded polytetrafluoroethlyene (ePTFE) was implanted as full-thickness LV wall patch replacement. At 1-week, 1-month, or 3-month intervals, pigs were terminated. After macroscopic examination, samples of tissue were prepared for histology, immunocytochemistry, and analysis of cell proportions by flow cytometry. One-week and 1-month patches were intact with thrombus and inflammation; at 1 month, there was also tissue with spindle-shaped cells in proteoglycan-rich and collagenous matrix. More alpha-smooth muscle actin-positive cells were present in urinary bladder matrix (UBM) than in ePTFE (22.2+/-3.3% versus 8.4+/-2.7%; P=0.04). At 3 months, UBM was bioresorbed, and a collagen-rich vascularized tissue with numerous myofibroblasts was present. Isolated regions of alpha-sarcomeric actin-positive, intensely alpha-smooth muscle actin-immunopositive, and striated cells were observed. ePTFE at 3 months had foreign-body response with necrosis and calcification. Flow cytometry showed similarities of cells from UBM to normal myocardium, whereas ePTFE had limited cardiomyocyte markers. CONCLUSIONS: Appearance of a fibrocellular tissue that included contractile cells accompanied biodegradation of UBM when implanted as an LV-free wall infarction patch. UBM appears superior to synthetic material for cardiac patching and trends toward myocardial replacement at 3 months.
BACKGROUND:Heart failure remains a significant problem. Tissue-engineered cardiac patches offer potential to treat severe heart failure. We studied an extracellular matrix scaffold for repairing the infarcted left ventricle. METHODS AND RESULTS:Pigs (n=42) underwent left ventricular (LV) infarction. At 6 to 8 weeks, either 4-layer multilaminate urinary bladder-derived extracellular matrix or expanded polytetrafluoroethlyene (ePTFE) was implanted as full-thickness LV wall patch replacement. At 1-week, 1-month, or 3-month intervals, pigs were terminated. After macroscopic examination, samples of tissue were prepared for histology, immunocytochemistry, and analysis of cell proportions by flow cytometry. One-week and 1-month patches were intact with thrombus and inflammation; at 1 month, there was also tissue with spindle-shaped cells in proteoglycan-rich and collagenous matrix. More alpha-smooth muscle actin-positive cells were present in urinary bladder matrix (UBM) than in ePTFE (22.2+/-3.3% versus 8.4+/-2.7%; P=0.04). At 3 months, UBM was bioresorbed, and a collagen-rich vascularized tissue with numerous myofibroblasts was present. Isolated regions of alpha-sarcomeric actin-positive, intensely alpha-smooth muscle actin-immunopositive, and striated cells were observed. ePTFE at 3 months had foreign-body response with necrosis and calcification. Flow cytometry showed similarities of cells from UBM to normal myocardium, whereas ePTFE had limited cardiomyocyte markers. CONCLUSIONS: Appearance of a fibrocellular tissue that included contractile cells accompanied biodegradation of UBM when implanted as an LV-free wall infarction patch. UBM appears superior to synthetic material for cardiac patching and trends toward myocardial replacement at 3 months.
Authors: John M Wainwright; Ryotaro Hashizume; Kazuro L Fujimoto; Nathaniel T Remlinger; Colin Pesyna; William R Wagner; Kimimasa Tobita; Thomas W Gilbert; Stephen F Badylak Journal: Cells Tissues Organs Date: 2011-10-24 Impact factor: 2.481
Authors: Udi Sarig; Gigi C T Au-Yeung; Yao Wang; Tomer Bronshtein; Nitsan Dahan; Freddy Y C Boey; Subbu S Venkatraman; Marcelle Machluf Journal: Tissue Eng Part A Date: 2012-07-19 Impact factor: 3.845
Authors: Seokwon Pok; Igor V Stupin; Christopher Tsao; Robia G Pautler; Yang Gao; Raymond M Nieto; Ze-Wei Tao; Charles D Fraser; Ananth V Annapragada; Jeffrey G Jacot Journal: Adv Healthc Mater Date: 2017-01-12 Impact factor: 9.933
Authors: Nathaniel T Remlinger; Thomas W Gilbert; Masahiro Yoshida; Brogan N Guest; Ryotaro Hashizume; Michelle L Weaver; William R Wagner; Bryan N Brown; Kimimasa Tobita; Peter D Wearden Journal: Organogenesis Date: 2013-06-25 Impact factor: 2.500
Authors: Damon J Kelly; Amy B Rosen; Adam J T Schuldt; Paul V Kochupura; Sergey V Doronin; Irina A Potapova; Evren U Azeloglu; Stephen F Badylak; Peter R Brink; Ira S Cohen; Glenn R Gaudette Journal: Tissue Eng Part A Date: 2009-08 Impact factor: 3.845
Authors: Jennifer M Singelyn; Jessica A DeQuach; Sonya B Seif-Naraghi; Robert B Littlefield; Pamela J Schup-Magoffin; Karen L Christman Journal: Biomaterials Date: 2009-07-15 Impact factor: 12.479